Dose escalation will continue with each new cohort in accordance with the rules described in the following table. The dose below that at which dose escalation is stopped will be considered the Optimal Biological Dose (OBD) and this dose will be the starting dose used in Part II of the study which will assess repeat dosing with acadesine. The OBD will be reviewed by the DMB prior to the start of Part II of the study.